Cover image of the article: The efficacy of oral ribavirin in treatment of Crimean-Congo hemorrhagic fever in Iran

Image Credit:J Inflamm Dis

The efficacy of oral ribavirin in treatment of Crimean-Congo hemorrhagic fever in Iran

Authors

M Mardani, M Keshtkar Jahromi,*, K Holakoi Naini, M Zinali
*Corresponding Author: Email: mkeshtkarjahromi@mail.com

Journal of Inflammatory Diseases:Vol. 7, issue 3; 34-38
Published online:Nov 01, 2003
Article type:Research Article
How to Cite:Mardani M, Keshtkar Jahromi M, Holakoi Naini K, Zinali M. The efficacy of oral ribavirin in treatment of Crimean-Congo hemorrhagic fever in Iran. J Inflamm Dis. 2024;7(3):e154958. doi:

Abstract

Background: Crimean-Congo Hemorrhagic fever is a fatal viral disease that occurs in some parts of Africa, Asia, Eastern Europe and Middle-East. Primarily it is a zoonosis but can be seen sporadically in humans. Recently outbreaks have been reported from Pakistan, Afghanistan, Saudi Arabia, United Arab Emirates and Iran. Objective: This study was performed to determine the effecacy of oral ribavirin in treament of CCHF cases by comparing the outcome in two treated and non-treated confirmed CCHF cases. Methods: In this retrospective study 81 confirmed CCHF cases (by serology or viral culture) were evaluated for the incidence of outcome (death or recovery) in the from of an analytic case-control study. Results were analyzed by statistical tests. Findings: From 69 proved CCHF cases who were treated by oral ribavirin and 12 cases who had received no drugs, 61 and 5 cases were survived respectively. Conclusion: Oral ribavirin with an efficacy of 91% can be an effective medical therapy for management of Crimean-Congo hemorrhagic fever.

Highlights

Copyright

© 2024, Journal of Inflammatory Diseases. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

31
Jan
2012

Crimean-Congo Hemorrhagic Fever

Masoud Mardani

Mardani M. Crimean-Congo Hemorrhagic Fever. Arch Clin Infect Dis. 2012;7(1):. doi:

28
Apr
2021
A Systematic Review of Treatment Strategies Including Future Novel Therapies in Crimean-Congo Hemorrhagic Fever

A Systematic Review of Treatment Strategies Including Future Novel Therapies in Crimean-Congo Hemorrhagic Fever

Hamidreza Kouhpayeh

Kouhpayeh H. A Systematic Review of Treatment Strategies Including Future Novel Therapies in Crimean-Congo Hemorrhagic Fever. Int J Infect. 2021;8(2):e113427. doi: https://doi.org/10.5812/iji.113427

12
Jun
2017
Effects of Dexamethasone on Clinical Outcome in Patients with Severe Crimean-Congo Hemorrhagic Fever

Effects of Dexamethasone on Clinical Outcome in Patients with Severe Crimean-Congo Hemorrhagic Fever

Mohammad Hashemi-Shahri,
Batool Sharifi-Mood,
Alireza Ansari Moghaddam,
Shahabodin Mashaei

Hashemi-Shahri M, Sharifi-Mood B, Ansari Moghaddam A, Mashaei S. Effects of Dexamethasone on Clinical Outcome in Patients with Severe Crimean-Congo Hemorrhagic Fever. Int J Infect. 2017;4(3):e14587. doi: https://doi.org/10.5812/iji.14587

31
Dec
2016
Report of the first case of Crimean Congo hemorrhagic fever in Qazvin province (2016)

Report of the first case of Crimean Congo hemorrhagic fever in Qazvin province (2016)

A Nikoonejad,
Behzad Bijani

Nikoonejad A, Bijani B. Report of the first case of Crimean Congo hemorrhagic fever in Qazvin province (2016). J Inflamm Dis. 2024;20(5):e155994. doi:

30
Nov
2011

Optional Modalities for Treatment of Patients with Severe Crimean-Congo Hemorrhagic Fever

Batool Sharifi Mood,
Maliheh Metanat,
Roya Alavi Naini,
Masoud Mardani,
Ali Amjadi

Sharifi Mood B, Metanat M, Alavi Naini R, Mardani M, Amjadi A. Optional Modalities for Treatment of Patients with Severe Crimean-Congo Hemorrhagic Fever. Arch Clin Infect Dis. 2011;6(Suppl):. doi:

More by these authors

M MardaniPubMedScholar
M Keshtkar JahromiPubMedScholar
K Holakoi NainiPubMedScholar
Share
Cited by
Metrics